AXL inhibitor treatment in mice, reduces the proportion of dormant myeloma cells and increases tumour burden, suggesting disruption of the AXL-GAS6 axis inhibits dormancy and thereby triggers reactivation [29]. The gene discussed is GAS6; the disease is plasma cell myeloma.